NCT04161235View on ClinicalTrials.gov

Post-Market Clinical Evaluation of the Zephyr Valve 5.5-LP EBV

CompletedOBSERVATIONAL
Enrollment

2

Participants

Timeline

Start Date

February 5, 2020

Primary Completion Date

August 13, 2021

Study Completion Date

December 30, 2021

Conditions
Pulmonary Emphysema
Interventions
DEVICE

The Pulmonx Zephyr Endobronchial Valve (EBV) 5.5- LP

The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.

Trial Locations (3)

8091

University Hospital of Zurich, Zurich

45239

Ruhrlandklinik Essen - Universitätsmedizin, Essen

SW3 6NP

Royal Brompton Hospital, London

All Listed Sponsors
lead

Pulmonx Corporation

INDUSTRY

NCT04161235 - Post-Market Clinical Evaluation of the Zephyr Valve 5.5-LP EBV | Biotech Hunter | Biotech Hunter